We describe a method for producing specific PCR primers directly from PCR product, bypassing the usual need to know the primer sequence. Lack of abundance of primers derived from a PCR product is compensated for by the incorporation of an arbitrary 5′TAG sequence which acts as a surrogate template target for the bulk amplification phase. We use the technique to amplify clonospecific rearranged immunoglobulin genes, which have applications as markers of lymphoid neoplasms for tracing the success of therapy. The principle may have wider application wherever conserved and variable regions of DNA are juxtaposed.
INTRODUCTION
The essence of PCR is that abundant specific primers flanking a target DNA region of interest are used to generate multiple copies of that region. Conventionally, this process requires chemical synthesis of primers of known sequence. Where highly variable regions of DNA occur adjacent to more conserved regions, as is the case for rearranged immunoglobulin genes, we questioned how the conserved sequence might be used as a 'handle' to prime specifically through the variable sequence, without the requirement to determine the variable sequence in each case. Rearranged immunoglobulin genes ( Fig. 1 ) have huge diversity created by the process of VDJ joining, and are effectively clonospecific markers for leukaemias of lymphoid origin. Their use has been exploited in haematological practice to detect rare leukaemic cells, undetectable by conventional light microscopy, a state termed 'Minimal Residual Disease' (1, 2) .
Hitherto, sensitive methods for using these markers have required the isolation and sequencing of the rearranged genes. 'Fingerprinting' methods are a simpler alternative, which use consensus PCR primers for conserved framework regions ( Fig. 1 ), but have more limited specificity (3, 4) . This paper describes the use of 5′TAG sequences (5) to permit a novel approach to generation of clonospecific primers direct from V-region amplicons, which we term 'biologically-generated clone-specific primer' (BG-CSP). A major objection to the use of amplicons or their fragments as primers in new PCR reactions is that they are insufficiently abundant, as each new molecule of PCR product must stoichiometrically incorporate a single primer species. However, if the amplicon includes a 5′TAG sequence, arbitrarily chosen, unrelated to genomic template, fragments including this TAG can act as initiating primers for new PCR reactions which are carried to completion by provision of normal primer concentrations of the TAG sequence.
In order to generate a primer with 3′ specific sequence, as a fragment of an amplicon containing framework region at each end, we insert a restriction site, close to the 3′ end of the consensus primer, for an enzyme BsgI, which cuts 16 nt downstream of its recognition site. This overcomes the difficulty of specifying a restriction site that will be reliably present, within a region of inherent variability.
MATERIALS AND METHODS

DNA preparation
Blood and bone marrow samples were obtained from patients with clonal lymphoid disorders, principally acute lymphoblastic leukaemia (ALL) or chronic lymphocytic leukaemia (CLL), and from normal volunteers. Mononuclear cells were isolated by centrifugation on lymphoprep (Nycomed, UK). DNA extraction was performed using the Nucleon II kit (Scotlab, UK). DNA concentrations were determined by spectrophotometry at 260 nm.
PCR amplification
PCR reactions were performed in 50 µl volumes containing 1 µM concentration of each primer; 200 µM of dATP, dCTP, dGTP and dTTP; PCR buffer to provide a final concentration of 50 mM KCl and 10 mM Tris-HCl; 1.5 mM Mg 2+ , except for reactions with biologically-generated primers where the Mg 2+ concentration was 2.5 mM; 1.25 U of Amplitaq Gold DNA polymerase (Applied Biosystems); and appropriate sample template. Biologically generated primers were used at 1-2 nM, i.e. 500-1000-fold lower than standard primer concentration. Reactions were set up in a laminar air-flow cabinet, using PCR-dedicated pipettes and filter tips. Primers used were as follows: PCR reactions were performed on a Perkin-Elmer 480 thermocycler: All reactions were preceded by a denaturation step of 12 min at 94_C. For amplification across CDR3 regions using FR3 and LJH consensus primers or TAG1.FR3(BSG) and TAG2.JPS(BSG) or TAG2.JPS, 40 cycles were used of 94_C for 30 s followed by 56_C for 20 s. For amplification of total heavy chain V regions, LJH/JPS and either a consensus FR1 primer or a family-specific FR1 consensus primer were used. The latter requires determination in advance by PCR to which of the seven described human VH families (6) a particular clone belongs. Thirty-five cycles were used of 94_C for 40 s, 60_C for 60 s and 72_C for 40 s. For amplification with BG-CSP, TAG2 and FR2B, longer annealing times were used as both template and primer species are initially rare: 10 cycles of 94_C for 40 s, 70_C for 4 min and 72_C for 40 s were followed by 10 cycles of 94_C for 40 s, 70_C for 2 min and 72_C for 40 s, and a further 10-15 cycles of 94_C for 40 s, 70_C for 1 min and 72_C for 40 s.
Agarose and acrylamide gel electrophoresis
Electrophoresis of PCR products of 200 bp and larger was performed in 2% agarose TBE gels containing ethidium-bromide at 5 V/cm for 2-3 h. Amplified CDR3 regions (products of 80-120 bp length) were analysed on 20 20 cm 8% non-denaturing acrylamide gels cast on GelBond Pagfilm (Flowgen, UK). After electrophoresis for 90 min at 300 V, gels were fixed and silver-stained (7). For improved resolution of PCR products larger than 200 bp, 5% acrylamide gels (20 cm 20 cm) were used and electrophoresis carried out until the xylene cyanol dye front was 75% of the way down the gel.
Restriction enzyme digestion
Digestion of PCR products was carried out with BsgI enzyme (NEB, UK) in the presence of 80 µM S-adenosylmethionine. One microlitre of PCR product was incubated with 1 µl (2 U) of enzyme in a final volume of 10 µl for 2-3 h at 37_C.
Purification of the BG-CSP
BG-CSP (typically a digest of 1 µl of PCR product) was gel purified by using an adjacent silver-stained lane to identify the position of the desired fragment. The unstained fragment was extracted into 200 µl of TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0).
RESULTS
Protocol for production of BG-CSP
Our protocol for production of BG-CSP is shown in Figure 2 . Changes to the consensus primers required to insert the BsgI restriction sites are shown in Materials and Methods. Initial attempts to make two BG-CSPs for each clone, derived by digestion of a single PCR product containing two BsgI sites, proved unsuccessful. Thus, it was impossible to purify the desired 'primer' species (Fig. 2iv) away from minute quantities of uncut species (Fig. 2iii) . Our ultimate test protocol therefore used only the J-region BG-CSP in combination with an externally sited FR2B consensus primer for which full-length species remaining after BsgI digestion (Fig. 2iii) cannot act as template. Intriguingly, TAG1 which now becomes redundant as a means of amplification, serves another function (discussed below), so was preserved in the primer used for generating BG-CSP.
Introduction of the BsgI site in the J-region requires substitution of nucleotides at positions 4, 5 and 6 from the 3′ end of the consensus primer. Not surprisingly, attempts to amplify CDR3 region directly from genomic DNA using primers with substitutions so close to the critical 3′ end of the primer yielded a number of additional non-specific bands. Two alternative approaches could circumvent this problem. Firstly, a nested PCR could be used. If genomic DNA was first amplified with consensus FR3 to LJH primers, and a sample of this product was used as template in a second round of a nested PCR (Fig. 2) using consensus primers into which had been inserted the BsgI sites, TAG1.FR3(BSG) and TAG2.JPS(BSG), it was now possible to obtain sufficiently pure PCR products.
Alternatively, we used consensus primers with only a single BsgI site, placed in the FR3 consensus giving a variable specific sequence, on average 30-60 nt (depending on the length of the CDR3 region), plus adjacent consensus sequence and TAG. We have termed this species 'long BG-CSP' (Fig. 2 ' alternative protocol') to distinguish it from the majority shorter species produced when two BsgI sites are used. In the case of the FR3 consensus the nucleotides which must be changed to insert the Figure 2 . Production of BG-CSP. Our original protocol was performed as a nested PCR. Genomic DNA from a patient with a clonal lymphoid disorder (i) is amplified with FR3 and J-region consensus primers. The product (ii) provides template for a second step using FR3 and J-region primers both altered to introduce the BsgI restriction site (indicated by a double asterix) and each with a 5′TAG. Digestion of this second round product (iii) with BsgI produces the two fragments shown (iv) (as well as a small central fragment). Only the downstream fragment labelled 'BG-CSP' is used as patient-specific primer (see text). In an 'alternative protocol', only one BsgI site is inserted at step 2 by use of TAG1.FR3(BSG) and TAG2.JPS primers. Digestion of this product creates 'long BG-CSP'. An advantage of the latter protocol is that the first step of the PCR can be omitted.
BsgI site are presumably less critical than is the case for the J-region (two or three nucleotide changes but further from the 3′ end). Thus, the primers TAG1.FR3 (BSG) and TAG2.JPS could usually be used directly with template of genomic DNA to produce a PCR product of equivalent purity to that obtained in a nested PCR. A further advantage of 'long' BG-CSP was that it generally provided greater or equal sensitivity compared to 'short' BG-CSP.
Protocol for testing of the BG-CSP
A nested PCR protocol gave the best results. A first round amplification of test DNA was performed with the J-region consensus primer LJH/JPS combined with either a general FR1 or a 'family-specific' FR1 primer. In the second step of the nested PCR, FR2B forward primer is used in combination with the relevant BG-CSP at low concentration, and TAG2 supplied at First round PCR was performed using VH3 family-specific FR1 primer and LJH/JPS consensus primer. An aliquot (1 µl) of first round product was used as template for the second round PCR using patient E ('long') BG-CSP, TAG2 and FR2B as primers.
conventional primer concentrations, which drives the bulk amplification phase (Fig. 1 ).
Specificity and sensitivity of BG-CSP
To mimic the situation of Minimal Residual Disease in leukaemia we have tested the ability of BG-CSP to detect small amounts of its own clonal DNA in a background of normal DNA. BG-CSP had marked discriminatory power for its clone of origin, compared to a range of normal sequences, which was favoured by use of a high annealing temperature (70_C). Sensitivity of detection up to 1 part in 10 000 of clonal DNA:normal DNA was found under optimally chosen conditions. An example is shown for a patient with ALL (Fig. 3) . Some weak background amplification of normal DNA is also seen, though much less than that obtained with a 1 in 10 000 dilution of clonal DNA. Resolution in agarose gels was enhanced by electrophoresis times of 2-3 h (at 5 V/cm). However, in difficult cases where it may be harder to achieve specificity (e.g. due to a short CDR3 region), optimum resolution of a clonal band of interest from a polyclonal background could be achieved by electrophoresis on 5% acrylamide gels.
DISCUSSION
In this work we establish the principle of deriving PCR primer directly from a PCR product, obviating the need to know the primer sequence. These primers may be useful in haematological practice, for detecting minimal residual disease in ALL, or for documenting complete remissions in order to compare treatment strategies in CLL. Although a number of methods are available for this purpose, including those based on both PCR or radiolabelled probe, we believe our method is unique in allowing sensitivity of 1 part in 10 000, without either the use of radioactivity, or a requirement for sequencing (1) (2) (3) (4) . Avoidance of both of these factors may be desirable for a technique which might ultimately become part of routine clinical laboratory practice.
A potential problem of this technique is that the uncleaved V-region amplicon could be a highly efficient and non-clonospecific primer, as each end is anchored in a framework region. Indeed, attempts to 'simplify' the primer design for production of BG-CSP by removing the apparently redundant TAG1 from the 5′ end of the FR3 primer (Fig. 2, step 2) produced BG-CSP species markedly less specific than their counterparts produced using TAG in each direction. The unexpected benefit of TAG1 can be explained because the 3′ complement of the TAG1 sequence, being unrelated to genomic template fails to hybridise and is not a primer. Hence only amplicons successfully cleaved within the CDR3 region, and therefore having 3′ specific sequence, can act as BG-CSP.
Biologically-generated primers might be applicable to the analogous T-cell receptor gene rearrangements, but also in other systems where adjacent conserved and variable sequences are found, including that of viral variation. The important features defined here, including the use of the downstream cutting enzyme, the importance of one end of the region of test amplification lying external to the sequences used for production of BG-CSP, and the role of the additional TAG in conferring specificity, should be relevant for other systems.
